Lung factor is a research group and researcher network that aims in developing better diagnostics and therapeutics to idiopathic pulmonary fibrosis and mesothelioma. These diseases share common molecular pathways. The group involves clinical doctors and basic scientists, that work in close collaboration with the Helsinki Biobank and participates in ie. the FinnGen collaborative effort.
Idiopathic pulmonary fibrosis (IPF)

In 2012, the FinnishIPF registry study was initiated. Currently, it harbors around 800 IPF patients´ clinical data. The patients have given consent to participate to the study. All five university hospitals in Finland have formed a national IPF-consortium. In addition, all Finnish pulmonary care units have agreed to participate in the study. Our goal is to obtain comprehensive clinical patient cohorts for evaluation of IPF disease course. Together with the biobank of the National Institute for Health and Welfare, a subcohort of FinnishIPF patients form the FinnIPF sample collection for genetic analysis. The study has been mainly funded by the Academy of Finland, the Sigrid Jusélius Foundation, and has received grants from Boehringer Ingelheim, Roche and Orionpharma. For results, please see more from our latest publications.


Mesothelioma and Lung cancer

The research group has started a sample collection together with the Helsinki Biobank with the aim to detect biomarkers for malignant mesothelioma and lung cancer. Mesothelioma is a cancer of the lung sack with high resistance to conventional cancer therapies and a strong association to occupational asbestos exposure. The study has been funded by the Finnish Work Environment Fund, The Helsinki University Hospital, the Finnish Cancer Foundation and the University of Helsinki. For results, please see more from our latest publications.